key: cord-0888057-wj4u5mge
authors: Pallett, Scott John Charles; Jones, Rachael; Pallett, Mitchell Anthony; Rayment, Michael; Mughal, Nabeela; Davies, Gary William; Moore, Luke Stephen Prockter
title: Characterising differential antibody response is integral to future SARS-CoV-2 serostudies
date: 2020-07-31
journal: J Infect
DOI: 10.1016/j.jinf.2020.07.029
sha: 48a90e29dc21c351dac878f5a432224b51af75df
doc_id: 888057
cord_uid: wj4u5mge

nan

We read with interest data reported in this Journal by Tré-Hardy et al., 1 where they provide timely insight to challenges associated with implementing serological testing as an adjunct to SARS-CoV-2 surveillance. In areas where reporting of new cases has declined, consideration is being given to relaxation of social-distancing restrictions and considerable attention has been given to the supportive potential of serological testing in delayed identification of cases.

Tré-Hardy et al. demonstrate the urgent need to determine the optimal time from symptom onset for individual serological assays in order to develop suitable guidance on interpretation of results. As part of this process, we highlight further concerns around the potential interpretation of positive and negative results alike. A plethora of tests, designed for use as either point-of-care or laboratory-based assays have rapidly been developed, many having undergone limited validation in cases of severe, hospital infection and information around potentially inferred immunity has been at times vague. Increasing access to serological testing for SARS-CoV-2 has been available not only through private medical practices but also via high street providers, online, and in some cases via postal services. While national guidelines have gone some way to reduce the risk of confused messaging where clinicians are not directly involved in the resulting process, delayed reporting risks misinterpretation that may affect social-distancing behaviours.

The degree of immunity conferred from infection with SARS-CoV-2 remains unclear. Four major viral structural proteins have been identified (spike, envelope, nucleocapsid, and membrane). 2 Initial B cell response in SARS-CoV-2 infection appears to occur prior to the recovery phase, 3 and while antibody responses are thought to arise first to the nucleocapsid (NP) in SARS-CoV-1, it is the spike protein (essential in virus attachment and cell entry) and specifically the receptor-binding-domain (RBD) for which neutralizing antibodies have been identified. 4 Early work has also shown anti-RBD antibodies have some correlation with neutralization in SARS-CoV-2. 5 In addition to this humoral response, there is evidence of a multi-faceted reaction in the early phase of SARS-CoV-2 infection involving not only antibody-secreting B cells, but also follicular T helper cells, activated CD4 + cells and CD8 + T cells prior to the recovery of symptoms. 3 In addition to observations by Tré-Hardy et al. we would further state that the antibody target employed is integral to the potential interpretation of results. Currently available serological assays tend to target either non-neutralizing antibodies or rarely the likely neutralizing anti-RBD antibody. Differentiation between test targets by the wider public is an unrealistic expectation. Using an online repository of available assays, 6 and cross-referencing against regulatory body and advisory lists, we identified 284 currently available assays ( Figure 1 ).

Having analysed product descriptions and, where available, instruction leaflets and regulatory documentation submitted for approvals we find that the majority (168/284, 59.2%) make only vague reference to SARS-CoV-2 antigens or antibodies and some no reference whatsoever (49/284, 17.3%). Where manufacturers specify antibody targets, this is most commonly to the NP (36/284, 12.7%). 19/284 (6.7%) specify spike protein targets, 12/284 Therapeutic Goods Administration, Health Information and Quality Authority, World Health Organisation). Information was taken directly from product listings and inserts on manufacturer and/or distributor sites and cross-referenced against documentation available for product regulatory approval. Circle size is relative to number of assays found within that category and recorded as: declines, opportunity to assess assay performance, and concordance across different targets, is limited. If, for example, the anti-RBD antibodies are confirmed as having neutralizing activity and direct comparison finds complete concordance with antinucleocapsid assays then this concern becomes less immediately urgent. If considerable variation between assays exists however, then it is crucial for assay manufacturers to be more explicit in their target design and more specific in advice around test utility. Those assays utilizing non-neutralizing targets could then have limited utility in delayed case identification but should never then confer a sense of immunity. Regardless, it must be remembered that these tests primarily offer a qualitative detection of antibody at a single time point and are unable to infer any sense of memory, or whether the humoral response to the primary infection is sufficient to lead to any level of protection. Even assays that do detect anti-RBD antibodies, presuming they are shown to have some lasting neutralizing effect in vivo, could only be considered a suggestion of immunity. Observation of reduced levels of neutralizing antibody in convalescent patients at just 2-3 months precludes antibody detection testing as a form of 'immunity passport'. 10 Where the rate of acute infection is significantly declining in some areas, longitudinal studies characterizing the immune response in both symptomatic and asymptomatic individuals with confirmed infection is now urgently required. Full benefit of antibody screening programmes will only be realised where clear information is available for researchers around assay targets.

We further calls by Tré-Hardy et al. for the need to establish appropriate timeframes for serological testing in order to minimise misinterpretation but also feel better understanding of the differential antibody response and transparent assay target information is essential to inform this process. While comparative, longitudinal studies between assay targets are urgently required, messaging on social-distancing and the appropriate use of personal protective equipment, regardless of a result, must remain a mainstay. If this is unable to be effectively delivered where kits are being used in the community, then testing for the purposes of delayed case identification alone should be limited to where direct clinical counselling can be undertaken.

The role of serology for COVID-19 control: Population, kinetics and test performance do matter

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

The trinity of COVID-19: immunity, inflammation and intervention

The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement

Point-of-care serological assays for SARS-CoV-2 in a UK hospital population: potential for enhanced case finding

Point-of-care serological assays for delayed SARS-CoV-2 case identification among UK healthcare workers

Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak

Online ahead of print

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

SJCP & LSPM designed the methodology. SJCP & MAP collected the data. All authors reviewed the results and data analysis and contributed comments. SJCP drafted the initial manuscript with all authors contributing significantly to revising this for submission. All authors agreed on the final version for submission to the journal.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

No patient information is involved in this submission. 

The data analysed during the current study and further details on the assays are available from the corresponding author (SJCP; scott.pallett@nhs.net) on reasonable request, as long as this meets local ethical and research governance criteria.